Skip to main content
Top
Published in: World Journal of Surgery 7/2007

01-07-2007

Significance of CD44 Expression in Gastrointestinal Stromal Tumors in Relation to Disease Progression and Survival

Authors: Kai-Hsi Hsu, Hung-Wen Tsai, Yan-Shen Shan, Pin-Wen Lin

Published in: World Journal of Surgery | Issue 7/2007

Login to get access

Abstract

Background

CD44 is a transmembrane glycoprotein belonging to the cell-adhesion molecule family. It has been identified as being involved in tumor progression and metastasis, and its expression has been found to be of prognostic significance in several human malignancies. The aim of this study was to assess CD44 expression in gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumor of the gastrointestinal tract.

Methods

Between January 1995 and March 2006, 92 patients undergoing surgical resection for GIST in National Cheng Kung University Hospital were evaluated. To study the significance of CD44 expression, immunohistochemical staining of CD44 in tumor specimens was performed, and the clinicopathological information of patients was reviewed.

Results

Fifty-nine of 81 patients (73%) showed positive CD44 expression. Loss of CD44 expression was associated with disease progression (p = 0.019). Kaplan-Meier analysis revealed better progression-free survival among patients with strong CD44 expression (++ and +++) (p = 0.034), absence of disease progression (p < 0.001), and lower risk, according to National Institutes of Health (NIH) Consensus Criteria for GIST risk stratification (p = 0.003). Multivariate analysis demonstrated that high-risk status was the only independent risk factor for disease progression and the only independent predictor for a poor progression-free survival (p = 0.023 and 0.045, respectively).

Conclusions

It is demonstrated that high-risk status by NIH criteria is significantly associated with disease progression and poor progression-free survival in GIST.
Literature
1.
go back to reference Screaton GR, Bell MV, Jackson DG, et al. (1992) Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89:12160–12164PubMedCrossRef Screaton GR, Bell MV, Jackson DG, et al. (1992) Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89:12160–12164PubMedCrossRef
2.
go back to reference Trowbridge I, Lesley J, Schulte R, et al. (1982) Biochemical characterization and cellular distribution of a polymorphic, murine cellsurface glycoprotein expressed in lymphoid tissues. Immunogenetics 15:299–312PubMedCrossRef Trowbridge I, Lesley J, Schulte R, et al. (1982) Biochemical characterization and cellular distribution of a polymorphic, murine cellsurface glycoprotein expressed in lymphoid tissues. Immunogenetics 15:299–312PubMedCrossRef
3.
go back to reference Naor D, Sionov RV, Ish-Shalom D. (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241–319PubMed Naor D, Sionov RV, Ish-Shalom D. (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241–319PubMed
4.
go back to reference Tolg C, Hoffman M, Herrlich P, et al. (1993) Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acid Res 21:1225–1229PubMedCrossRef Tolg C, Hoffman M, Herrlich P, et al. (1993) Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acid Res 21:1225–1229PubMedCrossRef
5.
go back to reference Soukka T, Salmi M, Joensuu H, et al. (1997) Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 57:2281–2289PubMed Soukka T, Salmi M, Joensuu H, et al. (1997) Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 57:2281–2289PubMed
6.
go back to reference Aruffo A, Stamenkovic I, Melnick M, et al. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303–1313PubMedCrossRef Aruffo A, Stamenkovic I, Melnick M, et al. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303–1313PubMedCrossRef
7.
go back to reference Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35:211–231PubMedCrossRef Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35:211–231PubMedCrossRef
8.
go back to reference Sneath RJ, Mangham DC (1998) The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51:191–200PubMedCrossRef Sneath RJ, Mangham DC (1998) The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51:191–200PubMedCrossRef
9.
go back to reference Gunthert U, Hofmann M, Rudy W, et al. (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13–24PubMedCrossRef Gunthert U, Hofmann M, Rudy W, et al. (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13–24PubMedCrossRef
10.
go back to reference Granberg D, Wilander E, Oberg K, et al. (1999) Decreased survival in patients with CD44-negitive typical bronchial carcinoid tumors. Int J Cancer 84:484–488PubMedCrossRef Granberg D, Wilander E, Oberg K, et al. (1999) Decreased survival in patients with CD44-negitive typical bronchial carcinoid tumors. Int J Cancer 84:484–488PubMedCrossRef
11.
go back to reference Humphrey G, Hazel DL, MacLennan K, et al. (1999) Expression of CD44 by rhabdomyosarcoma: a new prognostic marker? Br J Cancer 80:918–921PubMedCrossRef Humphrey G, Hazel DL, MacLennan K, et al. (1999) Expression of CD44 by rhabdomyosarcoma: a new prognostic marker? Br J Cancer 80:918–921PubMedCrossRef
12.
go back to reference Kahara N, Ozaki T, Doi T, et al. (2000) CD44 expression in soft tissue sarcomas. Virchows Arch 436:574–578PubMedCrossRef Kahara N, Ozaki T, Doi T, et al. (2000) CD44 expression in soft tissue sarcomas. Virchows Arch 436:574–578PubMedCrossRef
13.
go back to reference Poncelet C, Walker F, Madelenat P, et al. (2001) Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol 32:1190–1196PubMedCrossRef Poncelet C, Walker F, Madelenat P, et al. (2001) Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol 32:1190–1196PubMedCrossRef
14.
go back to reference Peiper M, Sato T, Zurakowski D (2004) CD44s expression is associated with improved survival in soft tissue sarcoma. Anticancer Res 24:1053–1056PubMed Peiper M, Sato T, Zurakowski D (2004) CD44s expression is associated with improved survival in soft tissue sarcoma. Anticancer Res 24:1053–1056PubMed
15.
go back to reference Diaz LK, Zhou X, Wright ET, et al. (2005) CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11:3309–3314PubMedCrossRef Diaz LK, Zhou X, Wright ET, et al. (2005) CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11:3309–3314PubMedCrossRef
16.
go back to reference Lai CH, Shan YS, Sy ED, et al. (2005) The significance of CD44 expression in gastrointestinal neuroendocrine tumors. Hepatogastroenterology 52:1071–1076PubMed Lai CH, Shan YS, Sy ED, et al. (2005) The significance of CD44 expression in gastrointestinal neuroendocrine tumors. Hepatogastroenterology 52:1071–1076PubMed
17.
go back to reference Kindblom LG, Remotti HE, Aldenborg F, et al. (1998) Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269PubMed Kindblom LG, Remotti HE, Aldenborg F, et al. (1998) Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269PubMed
18.
go back to reference Hirota S, Isozaki K, Moriyama Y, et al. (1998) Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRef Hirota S, Isozaki K, Moriyama Y, et al. (1998) Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRef
19.
go back to reference Demetri GD, Mehren MV, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRef Demetri GD, Mehren MV, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRef
20.
go back to reference Savage DG, Antman KH (2002) Imatinib mesylate—a new oral targeted therapy. N Engl J Med 346:683–693PubMedCrossRef Savage DG, Antman KH (2002) Imatinib mesylate—a new oral targeted therapy. N Engl J Med 346:683–693PubMedCrossRef
21.
go back to reference Rubin BP, Singer S, Tsao C, et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121PubMed Rubin BP, Singer S, Tsao C, et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121PubMed
22.
go back to reference Roberts PJ, Eisenberg B (2002) Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38:S37–S38PubMedCrossRef Roberts PJ, Eisenberg B (2002) Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38:S37–S38PubMedCrossRef
23.
go back to reference Nilsson B, Bumming P, Meis-Kindblom JM, et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer 103:821–829PubMedCrossRef Nilsson B, Bumming P, Meis-Kindblom JM, et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer 103:821–829PubMedCrossRef
24.
go back to reference Iesalnieks I, Rummele P, Dietmaier W, et al. (2005) Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol 124:740–748PubMedCrossRef Iesalnieks I, Rummele P, Dietmaier W, et al. (2005) Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol 124:740–748PubMedCrossRef
25.
go back to reference Fletcher CD, Berman JJ, Corless C, et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459–465PubMedCrossRef Fletcher CD, Berman JJ, Corless C, et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459–465PubMedCrossRef
26.
go back to reference Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7:507–519PubMedCrossRef Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7:507–519PubMedCrossRef
27.
go back to reference Ropponen KM, Eskelinen MJ, Lipponen PK, et al. (1998) Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 33:301–309PubMedCrossRef Ropponen KM, Eskelinen MJ, Lipponen PK, et al. (1998) Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 33:301–309PubMedCrossRef
28.
go back to reference Wielenga VJ, van der Neut R, Offerhaus GJ, et al. (2000) CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Adv Cancer Res 77:169–187PubMedCrossRef Wielenga VJ, van der Neut R, Offerhaus GJ, et al. (2000) CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Adv Cancer Res 77:169–187PubMedCrossRef
29.
go back to reference Bankfalvi A, Terpe HJ, Breukelmann D, et al. (1998) Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 33:107–116PubMedCrossRef Bankfalvi A, Terpe HJ, Breukelmann D, et al. (1998) Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 33:107–116PubMedCrossRef
30.
go back to reference Sun X, Gong Y, Talamonti MS, et al. (2002) Expression of cell adhesion molecule, CD44s and E-cadherin, and microvessel density in carcinoid tumors. Modern Pathol 15:1333–1338CrossRef Sun X, Gong Y, Talamonti MS, et al. (2002) Expression of cell adhesion molecule, CD44s and E-cadherin, and microvessel density in carcinoid tumors. Modern Pathol 15:1333–1338CrossRef
31.
go back to reference Montgomery E, Abraham SC, Fisher C, et al. (2004) CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 28:168–177PubMedCrossRef Montgomery E, Abraham SC, Fisher C, et al. (2004) CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 28:168–177PubMedCrossRef
32.
go back to reference Sugino T, Gorham H, Yoshida K, et al. (1996) Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149:873–882PubMed Sugino T, Gorham H, Yoshida K, et al. (1996) Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149:873–882PubMed
33.
go back to reference Okamoto I, Tsuiki H, Kenyon LC, et al. (2002) Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160:441–447PubMed Okamoto I, Tsuiki H, Kenyon LC, et al. (2002) Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160:441–447PubMed
34.
go back to reference Heinrich MC, Corless CL (2005) Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol 90:195–207PubMedCrossRef Heinrich MC, Corless CL (2005) Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol 90:195–207PubMedCrossRef
35.
go back to reference Yan H, Marchettini P, Acherman YI, et al. (2003) Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 26:221–228PubMedCrossRef Yan H, Marchettini P, Acherman YI, et al. (2003) Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 26:221–228PubMedCrossRef
36.
go back to reference Kwon SJ (2001) Korean Gastric Cancer Study Group. Surgery and prognostic factors for gastric stromal tumor. World J Surg 25:290–295PubMedCrossRef Kwon SJ (2001) Korean Gastric Cancer Study Group. Surgery and prognostic factors for gastric stromal tumor. World J Surg 25:290–295PubMedCrossRef
37.
go back to reference Steinert DM, Oyarzo M, Wang X, et al. (2006) Expression of Bcl-2 in gastrointestinal stromal tumors correlation with progression-free survival in 81 patients treated with Imatinib Mesylate. Cancer 106:1617–1623PubMedCrossRef Steinert DM, Oyarzo M, Wang X, et al. (2006) Expression of Bcl-2 in gastrointestinal stromal tumors correlation with progression-free survival in 81 patients treated with Imatinib Mesylate. Cancer 106:1617–1623PubMedCrossRef
38.
go back to reference Stewart AE, Heslin MH, Arch J, et al. (2006) Cyclooxygenase-2 expression and clinical outcome in gastrointestinal stromal tumors. J Gastrointest Surg 10:315–319PubMedCrossRef Stewart AE, Heslin MH, Arch J, et al. (2006) Cyclooxygenase-2 expression and clinical outcome in gastrointestinal stromal tumors. J Gastrointest Surg 10:315–319PubMedCrossRef
39.
go back to reference Takahashi R, Tanaka S, Kitadai Y, et al. (2003) Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64:266–274PubMedCrossRef Takahashi R, Tanaka S, Kitadai Y, et al. (2003) Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64:266–274PubMedCrossRef
40.
go back to reference Dei Tos AP (2003) The reappraisal of gastrointestinal stromal tumors: from stout to the KIT revolution. Virchows Arch 442:421–428PubMed Dei Tos AP (2003) The reappraisal of gastrointestinal stromal tumors: from stout to the KIT revolution. Virchows Arch 442:421–428PubMed
41.
go back to reference Rudolph P, Gloeckner K, Parwaresch R, et al. (1998) Immunophenotype, proliferation, DNA-ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathological study. Hum Pathol 29:791–800PubMedCrossRef Rudolph P, Gloeckner K, Parwaresch R, et al. (1998) Immunophenotype, proliferation, DNA-ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathological study. Hum Pathol 29:791–800PubMedCrossRef
42.
go back to reference Singer S, Rubin BP, Lux ML, et al. (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20:3898–3905PubMedCrossRef Singer S, Rubin BP, Lux ML, et al. (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20:3898–3905PubMedCrossRef
Metadata
Title
Significance of CD44 Expression in Gastrointestinal Stromal Tumors in Relation to Disease Progression and Survival
Authors
Kai-Hsi Hsu
Hung-Wen Tsai
Yan-Shen Shan
Pin-Wen Lin
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 7/2007
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-007-9088-1

Other articles of this Issue 7/2007

World Journal of Surgery 7/2007 Go to the issue

Reply

Reply

Letter

Reply